These findings suggest that pharmacological KV7.4 activation holds great potential as a novel therapeutic approach for ARHL by preventing or decelerating age-related decline of auditory function and morphological loss of OHCs, as well as for other hearing impairments related to compromised KV7.4 function. The gene discussed is KCNQ4; the disease is hearing loss disorder.